Clinical Trial Detail

NCT ID NCT02075840
Title A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants (ALEX)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Hoffmann-La Roche
Indications

lung non-small cell carcinoma

Therapies

Alectinib

Crizotinib

Age Groups: adult senior

Additional content available in CKB BOOST